Esperion Historical Income Statement

ESPR Stock

USD 1.69 0.04 2.31%

Historical analysis of Esperion Therapeutics income statement accounts such as Gross Profit of 62.5 M or Other Operating Expenses of 328.3 M can show how well Esperion Therapeutics performed in making a profits. Evaluating Esperion Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Esperion Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Esperion Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Esperion Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.

About Esperion Income Statement Analysis

Esperion Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Esperion Therapeutics shareholders. The income statement also shows Esperion investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Esperion Therapeutics Income Statement Chart

At this time, Esperion Therapeutics' Depreciation And Amortization is relatively stable compared to the past year. As of 02/26/2025, Interest Expense is likely to grow to about 71.2 M, though Operating Income is likely to grow to (133 M).

Other Operating Expenses Research Development Total Operating Expenses Selling General Administrative

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Esperion Therapeutics. It is also known as Esperion Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Esperion Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Esperion Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Esperion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.At this time, Esperion Therapeutics' Depreciation And Amortization is relatively stable compared to the past year. As of 02/26/2025, Interest Expense is likely to grow to about 71.2 M, though Operating Income is likely to grow to (133 M).

	2024	2025 (projected)
Interest Income	4.0M	3.5M
Reconciled Depreciation	287.5K	432.3K

Interest Income Reconciled Depreciation

Esperion Therapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Net Income	Income Tax Expense	Total Revenue	Income Before Tax	Total Other Income Expense Net	Selling General Administrative	Net Income From Continuing Ops	Non Operating Income Net Other	Net Interest Income	Reconciled Depreciation	Interest Income	Selling And Marketing Expenses
Depreciation And Amortization		-0.03	-0.16	0.3	-0.13	-0.14	0.55	-0.13	0.56	0.35	-0.13	0.2	-0.14	-0.09	0.05	0.15	-0.07	0.54	0.0	0.15	0.09	0.06
Interest Expense	-0.03		-0.34	0.78	-0.58	-0.56	0.27	-0.56	-0.04	0.7	-0.72	0.38	-0.34	-0.73	-0.98	0.84	-0.75	0.55	-0.98	0.52	-0.64	-0.93
Gross Profit	-0.16	-0.34		-0.56	0.58	0.58	-0.56	0.58	-0.34	-0.56	0.54	-0.22	1.0	0.58	0.33	-0.44	0.52	-0.54	0.36	-0.28	0.17	0.3
Other Operating Expenses	0.3	0.78	-0.56		-0.82	-0.81	0.76	-0.81	0.36	0.99	-0.86	0.47	-0.55	-0.87	-0.76	0.93	-0.87	0.74	-0.78	0.67	-0.44	-0.65
Operating Income	-0.13	-0.58	0.58	-0.82		1.0	-0.8	1.0	-0.5	-0.82	0.96	-0.55	0.58	0.98	0.59	-0.67	0.97	-0.82	0.62	-0.55	0.16	0.58
Ebit	-0.14	-0.56	0.58	-0.81	1.0		-0.8	1.0	-0.51	-0.82	0.96	-0.55	0.58	0.97	0.57	-0.66	0.96	-0.81	0.61	-0.55	0.15	0.57
Research Development	0.55	0.27	-0.56	0.76	-0.8	-0.8		-0.8	0.78	0.81	-0.71	0.38	-0.55	-0.72	-0.26	0.5	-0.69	0.75	-0.3	0.4	-0.02	-0.2
Ebitda	-0.13	-0.56	0.58	-0.81	1.0	1.0	-0.8		-0.5	-0.82	0.96	-0.55	0.58	0.97	0.57	-0.66	0.96	-0.81	0.61	-0.55	0.15	0.57
Cost Of Revenue	0.56	-0.04	-0.34	0.36	-0.5	-0.51	0.78	-0.5		0.4	-0.32	-0.07	-0.32	-0.38	0.11	0.02	-0.37	0.63	0.06	-0.13	-0.04	0.07
Total Operating Expenses	0.35	0.7	-0.56	0.99	-0.82	-0.82	0.81	-0.82	0.4		-0.85	0.5	-0.56	-0.86	-0.69	0.91	-0.85	0.74	-0.71	0.7	-0.36	-0.58
Net Income	-0.13	-0.72	0.54	-0.86	0.96	0.96	-0.71	0.96	-0.32	-0.85		-0.7	0.54	0.99	0.75	-0.77	0.98	-0.8	0.78	-0.69	0.2	0.74
Income Tax Expense	0.2	0.38	-0.22	0.47	-0.55	-0.55	0.38	-0.55	-0.07	0.5	-0.7		-0.23	-0.59	-0.5	0.5	-0.58	0.43	-0.49	0.85	0.19	-0.55
Total Revenue	-0.14	-0.34	1.0	-0.55	0.58	0.58	-0.55	0.58	-0.32	-0.56	0.54	-0.23		0.58	0.33	-0.44	0.52	-0.53	0.36	-0.28	0.17	0.31
Income Before Tax	-0.09	-0.73	0.58	-0.87	0.98	0.97	-0.72	0.97	-0.38	-0.86	0.99	-0.59	0.58		0.75	-0.76	1.0	-0.81	0.77	-0.61	0.26	0.72
Total Other Income Expense Net	0.05	-0.98	0.33	-0.76	0.59	0.57	-0.26	0.57	0.11	-0.69	0.75	-0.5	0.33	0.75		-0.84	0.76	-0.53	1.0	-0.58	0.47	0.92
Selling General Administrative	0.15	0.84	-0.44	0.93	-0.67	-0.66	0.5	-0.66	0.02	0.91	-0.77	0.5	-0.44	-0.76	-0.84		-0.77	0.57	-0.85	0.77	-0.46	-0.7
Net Income From Continuing Ops	-0.07	-0.75	0.52	-0.87	0.97	0.96	-0.69	0.96	-0.37	-0.85	0.98	-0.58	0.52	1.0	0.76	-0.77		-0.79	0.79	-0.62	0.3	0.75
Non Operating Income Net Other	0.54	0.55	-0.54	0.74	-0.82	-0.81	0.75	-0.81	0.63	0.74	-0.8	0.43	-0.53	-0.81	-0.53	0.57	-0.79		-0.58	0.38	-0.22	-0.55
Net Interest Income	0.0	-0.98	0.36	-0.78	0.62	0.61	-0.3	0.61	0.06	-0.71	0.78	-0.49	0.36	0.77	1.0	-0.85	0.79	-0.58		-0.57	0.48	0.92
Reconciled Depreciation	0.15	0.52	-0.28	0.67	-0.55	-0.55	0.4	-0.55	-0.13	0.7	-0.69	0.85	-0.28	-0.61	-0.58	0.77	-0.62	0.38	-0.57		-0.16	-0.58
Interest Income	0.09	-0.64	0.17	-0.44	0.16	0.15	-0.02	0.15	-0.04	-0.36	0.2	0.19	0.17	0.26	0.47	-0.46	0.3	-0.22	0.48	-0.16		0.59
Selling And Marketing Expenses	0.06	-0.93	0.3	-0.65	0.58	0.57	-0.2	0.57	0.07	-0.58	0.74	-0.55	0.31	0.72	0.92	-0.7	0.75	-0.55	0.92	-0.58	0.59

Click cells to compare fundamentals

Esperion Therapeutics Account Relationship Matchups

Esperion Therapeutics income statement Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Depreciation And Amortization	547K	612K	500K	164K	188.6K	198.0K
Interest Expense	22.7M	46.4M	56.8M	59.0M	67.8M	71.2M
Gross Profit	225.2M	64.2M	48.5M	73.1M	65.8M	62.5M
Other Operating Expenses	348.9M	305.2M	255.0M	271.9M	312.7M	328.3M
Operating Income	(121.4M)	(226.7M)	(179.5M)	(155.6M)	(140.0M)	(133.0M)
Ebit	(120.9M)	(222.8M)	(176.8M)	(150.3M)	(135.2M)	(128.5M)
Research Development	146.9M	106.0M	118.9M	86.1M	99.0M	75.8M
Ebitda	(120.3M)	(222.1M)	(176.3M)	(150.1M)	(135.1M)	(128.3M)
Cost Of Revenue	2.4M	14.2M	27.0M	43.3M	49.8M	49.3M
Total Operating Expenses	346.6M	291.0M	228.0M	228.6M	262.9M	276.1M
Net Income	(166.2M)	(318.8M)	(287.8M)	(209.2M)	(188.3M)	(178.9M)
Income Tax Expense	22.6M	49.7M	54.2M	(3.9K)	(4.5K)	(4.3K)
Total Revenue	227.5M	78.4M	75.5M	116.3M	104.7M	99.5M
Income Before Tax	(143.6M)	(269.1M)	(233.7M)	(209.2M)	(188.3M)	(178.9M)
Total Other Income Expense Net	(22.2M)	(42.4M)	(54.2M)	(53.7M)	(48.3M)	(45.9M)
Selling General Administrative	180.3M	171.3M	97.8M	126.9M	146.0M	153.3M
Net Income From Continuing Ops	(143.6M)	(269.1M)	(233.7M)	(208.4M)	(187.6M)	(196.9M)
Non Operating Income Net Other	4.1M	515K	4.0M	2.7M	3.0M	2.3M
Net Income Applicable To Common Shares	(97.2M)	(143.6M)	(269.1M)	(233.7M)	(210.3M)	(220.8M)
Net Interest Income	(22.7M)	(46.4M)	(56.8M)	(58.2M)	(52.4M)	(49.8M)
Reconciled Depreciation	547K	612K	500K	250K	287.5K	432.3K

Pair Trading with Esperion Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Esperion Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Esperion Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Esperion Stock

0.6	OPT	Opthea Earnings Call Today	Pair Corr
0.56	GANX	Gain Therapeutics	Pair Corr
0.56	PHGE	Biomx Inc	Pair Corr
0.49	CUE	Cue Biopharma	Pair Corr
0.49	PFE	Pfizer Inc Aggressive Push	Pair Corr

The ability to find closely correlated positions to Esperion Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Esperion Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Esperion Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Esperion Therapeutics to buy it.

The correlation of Esperion Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Esperion Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Esperion Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Esperion Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Esperion Stock Analysis

When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Esperion Historical Income Statement

About Esperion Income Statement Analysis

Esperion Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Esperion Therapeutics income statement Correlations

Esperion Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Esperion Therapeutics income statement Accounts

Pair Trading with Esperion Therapeutics

Moving against Esperion Stock

Additional Tools for Esperion Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Revenue	+ 1.0	Gross Profit
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Net Income From Continuing Ops	+ 1.0	Income Before Tax
Net Interest Income	+ 1.0	Total Other Income Expense Net

Net Interest Income	- 0.98	Interest Expense
Total Other Income Expense Net	- 0.98	Interest Expense
Selling And Marketing Expenses	- 0.93	Interest Expense
Net Income From Continuing Ops	- 0.87	Other Operating Expenses
Income Before Tax	- 0.87	Other Operating Expenses
Income Before Tax	- 0.86	Total Operating Expenses